AL - PID Study

Autoimmune lymphoproliferative primary immunodeficiency



Information Sheet - Follow-up

Clinical contact person **Lab Contact** Prof. Dr. Stephan Ehl Miriam Groß PD Dr. Carsten Speckmann Dr. Anne Rensing-Ehl MEDICAL CENTER - UNIVERSITY OF FREIBURG MEDICAL CENTER - UNIVERSITY OF FREIBURG Center for Chronic Immunodeficiency Center for Chronic Immunodeficiency at Center for Translational Cell Research at Center for Translational Cell Research CCI - Advanced Diagnostics Unit Breisacher Str. 115 (1. OG) Breisacher Str. 115 (EG) D - 79106 Freiburg D - 79106 Freiburg Tel. + 49 (0) 761 270 - 71 010 / - 71 080 Tel. + 49 (0) 761 270 - 77 300 Fax + 49 (0) 761 270 - 45 990 Fax + 49 (0) 761 270 - 96 71 070 E-mail: stephan.ehl@uniklinik-freiburg.de E-mail: miriam.gross@uniklinik-freiburg.de carsten.speckmann@uniklinik-freiburg.de anne.rensing-ehl@uniklinik-freiburg.de

Update clinical data - AL- PID study cohort

Your patient has been enrolled into our AL - PID study cohort. Today we kindly ask you to provide us with the follow-up information on the CURRENT condition of your patient.

Shipment of blood samples - if possible

- Please send 10 ml if acceptable 15 ml EDTA blood and 3 ml serum (for small children: 2 - 5 ml EDTA blood and 1 ml serum).
- Please announce any material > 3 days before sending it. (via e-mail or phone, see Lab Contact)
- Send via express (delivery until 9 a.m.).
- For patients with German health insurance: please include transfer form (Überweisungsschein) for genetic analysis.
- Please also send the <u>follow-up sheet</u>. (IMPORTANT!)

Thank you for your cooperation!

Clinical contact person			
Name			
Phone	Fax		
E-mail			
Patient label - if applicable	Shipment of		
Name of patient		Date of blood sample	
		day / month / year	
	ml EDTA	day / month / year	





AL - PID Study Follow-up Sheet



PATIENT INFORMATION		Patient label - if app	plicable
		Name of patient	
Gender O female O ma	ale O diverse		
	are e		i
		Date of birth (day/month/year)	
NEW INFORMATION			
Has any diagnosis explaining	lymphoproliferation ar	nd cytopenia been established?	?
	Oyes Ono O	unknown	
If so, please specify:			
CLINICAL DEVELOPMENT	DURING THE LAS	T 12 MONTHS	
Lymphoproliferation			
Lymphadenopathy → (> 6 months, > 2 locations)	O yes O no O ur	nknown	
If yes, current status	O improved O sa	ame O got worse O new	occurrence
	O current status unk	known	
Splenomegaly \rightarrow		ınknown	
If yes, current status	- ,	ınd investigation) but not palp 	
	O palpable: cm be		distance unknown
	Current status unik	KIIOWII	
If yes, current status	O improved O sa		occurrence
	O current status unk	known	
Has the nationt been	0	almanum	
Has the patient been \rightarrow splenectomized?	O yes O no O ur	IKHOWH	
If yes, reason for splenectomy	<u> </u>		(year of splenectomy)
	O reason unknown		O year unknown
Hepatomegaly →	Oyes Ono Our	aknown	
If yes, current status	,	ind investigation) but not palp	ahle
in year carrent status			distance unknown
	O current status unk		notaries antinown
If you current status	O improved O sa	ame O got worse O new	0.00118800.00
If yes, current status	O improved O sa O current status unk	•	occurrence
$\textbf{Malignancy} \qquad \rightarrow $	O yes O no O ui	nknown	
If yes, type of malignancy			(year of diagnosis)
(e.g. lymphoma)	O type unknown		O year unknown

AL - PID Study Follow-up Sheet

Patient label - if applicable	
Name of patient	į
Date of birth (day/month/year)	_

Autoimmunity and infections (during the last 12 months)				
Anemia (Hb < 10 g/dl) \rightarrow	O yes	O no	Ounknown	
If yes, coomb's positive	O yes	O no	O not done	Ounknown
requiring immunosuppression / IVIG	O yes	O no	Ounknown	
Thrombocytopenia (Plt < $100.000/\mu$ l) \rightarrow	O yes	O no	Ounknown	
If yes, anti-platelet antibodies	O yes	O no	O not done	Ounknown
requiring immunosuppression / IVIG	O yes	O no	Ounknown	
Neutropenia (ANC < $1000/\mu$ l) \rightarrow	O yes	O no	Ounknown	
If yes, anti-neutrophil antibodies	O yes	O no	O not done	Ounknown
requiring immunosuppression / IVIG	O yes	O no	Ounknown	
Autoimmunity and infections (during the last	t 12 mo	nths)		
Inflammatory gut disease (frequent diarrhoea without infectious trigger OR histologic evidence)	O yes	O no	Ounknown	
Interstitial lung disease (assessed by CO ₂ diffusion capacity OR HRCT)	O yes	O no	Ounknown	
Bronchiectasis	O yes	O no	Ounknown	
Inflammatory brain disease (indicated by MRI AND/OR CSF investigation)	O yes	O no	Ounknown	
Inflammatory skin disease	O yes	O no	Ounknown	
Other autoimmunity /immunodysregulation (eg. liver, kidney, thyroid, joints)	O yes	O no	Ounknown	
If yes, please specify: O autoimmunity / immunodysregulation unknown				
Is the patient prone to infections ?	O yes	O no	O unknown	
If yes, bronchopulmonary infections	O yes	O no	Ounknown	
candidiasis	O yes	O no	Ounknown	
warts	O yes	O no	Ounknown	
systemic or chronic viral infections (eg. EBV, CMV, Noro, Adeno) If yes, please specify:	O yes	O no	Ounknown	
Systemic or chronic viral infections unknown				

AL - PID Study Follow-up Sheet

ï	Patient label - if applicable		
-	Name of patient		
:			
	Date of birth (day/month/year)		

		(day/montn/year)	
Hypogammaglobulinemia	O yes O no	O unknown	
If yes, current IgG value		│ │ │ │ │ │ │ │ │ │ │ │ │ │ │ │ │ O unknown	
Hyper-IgM	O yes O no	Ounknown	
If yes, current IgM value		O g/l O mg/dl O unknown	
CURRENT SITUATION			
Full blood count (determined on the day blood is drawn for diagnostic testing)			
Leucocytes	/ μl	O unknown	
Lymphocytes	%	O unknown	
Monocytes	%	O unknown	
Is the patient CURRENTLY treated with:			
Steroids	O yes O no	O unknown	
Other Immunosuppression	O yes O no ♣ please specify:	O unknown	
	\$ picase specify.	O other immunosuppression unknown	
Rituximab (last six months)	O yes O no	O unknown	
	♥ Date of the last	dose O Date unknown (day/month/year)	
IVIG/SCIG	O yes O no	O unknown	
Other specific therapy:			

Date _____ Signature of Physician _____